Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals
AssigneeClarity Pharmaceuticals Ltd
InventorsPaul Stephen Donnelly, Michelle Therese Ma, Denis Bernard Scanlon
Life of this patent
Estimating the term…
Abstract
The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilising the radiolabelled compounds of the invention.
Claims6
A method of producing a compound of formula (I),
- wherein:
- L is a nitrogen containing macrocyclic metal ligand;
- X is a linking moiety;
- Y is selected from the group consisting of OR, SR1 and N(R2)2;
- R is independently selected from the group consisting of H, an oxygen protecting group, optionally substituted C1-C12alkyl, optionally substituted C2-C12alkenyl, optionally substituted C2-C12alkynyl and optionally substituted C2-C12 heteroalkyl;
- R1 is independently selected from the group consisting of H, a sulfur protecting group, optionally substituted C1-C12alkyl, optionally substituted C2-C12alkenyl, optionally substituted C2-C12alkynyl and optionally substituted C2-C12 heteroalkyl;
- and
- each R2 is independently selected from the group consisting of H, a nitrogen protecting group, optionally substituted C1-C12alkyl, optionally substituted C2-C12alkenyl, optionally substituted C2-C12alkynyl and optionally substituted C2-C12 heteroalkyl;
- or a pharmaceutically acceptable salt or complex thereof, the method comprising:
- reacting an amino substituted metal chelating ligand or a metal complex thereof of the formula:
- L-NH2
- wherein L is a nitrogen containing macrocyclic metal ligand;
- with an activated dicarbonyl compound of the formula (III)
- wherein Z is O, S or NR2;
- and
- (b) isolating the compound of formula (I) or a metal complex thereof;
- wherein L is
- V is selected from the group consisting of N and CR4;
- each Rx and Ry are independently selected from the group consisting of H, CH3, CO2H, NO2, CH2OH, H2PO4, HSO3, CN, CONH2 and CHO;
- each p is independently an integer selected from the group consisting of 2, 3, and 4,
- R4 is selected from the group consisting of H, OH, halogen, NO2, NH2, optionally substituted C1-C12alkyl, optionally substituted C6-C18aryl, cyano, CO2R5, NHR5, N(R5)2 and a group of the formula:
- wherein
- X1 is a linking moiety;
- Y1 is selected from the group consisting of OR6, SR7, N(R8)2 and a molecular recognition moiety;
- wherein R5 is H or C1-C12alkyl,
- wherein R6 is selected from the group consisting of H, halogen, an oxygen protecting group, optionally substituted C1-C12alkyl, optionally substituted C2-C12-alkenyl, optionally substituted C2-C12alkynyl and optionally substituted C2-C12 heteroalkyl;
- wherein R7 is selected from the group consisting of H, halogen, a sulfur protecting group, optionally substituted C1-C12alkyl, optionally substituted C2-C12-alkenyl, optionally substituted C2-C12alkynyl and optionally substituted C2-C12 heteroalkyl;
- wherein R8 is independently selected from the group consisting of H, halogen, a nitrogen protecting group, optionally substituted C1-C12alkyl, optionally substituted C2-C12-alkenyl, optionally substituted C2-C12alkynyl and optionally substituted C2-C12 heteroalkyl.
Dependencies are inferred from the claim text.